StockNews.com initiated coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO – Free Report) in a research note issued to investors on Saturday. The firm issued a strong-buy rating on the stock. Separately, HC Wainwright cut Taro Pharmaceutical Industries from a buy rating to a neutral rating and set a $43.00 price target for the company. […]